QNCX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
81.1M
+455.8%
14.6M
-24.6%
19.4M
+44.1%
13.4M
+28.8%
10.4M
R&D
64.5M
+841.7%
6.8M
-45.7%
12.6M
+55.9%
8.1M
+23.3%
6.6M
SG&A
16.6M
+289.6%
4.3M
+17.4%
3.6M
+10.8%
3.3M
-1.8%
3.3M
Operating Income
-81087000
-455.8%
-14590000
+24.6%
-19353000
-44.1%
-13430000
-28.8%
-10427000
EBITDA
-81046000
-631.7%
-11076000
+53.5%
-23836000
-110.4%
-11328000
-9.0%
-10392000
Net Income
-75488000
-310.2%
35.9M
+191.0%
-39458000
-193.5%
-13442000
+16.2%
-16049000
EPS (Basic)
$-12.31
-117.1%
$72.00
+229.4%
$-55.65
-11.3%
$-50.00
+27.3%
$-68.75
EPS (Diluted)
$-12.31
-121.4%
$57.60
+203.5%
$-55.65
-11.3%
$-50.00
+27.3%
$-68.75
Shares (Diluted)
6.1M
+1234.6%
459.5K
-35.2%
709.0K
+162.8%
269.8K
+15.6%
233.4K
Quince Therapeutics (QNCX) โ€” Financials